BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

Zacks Investment Research News Agency

Yesterday•Zacks Investment Research

Stocks Medium Importance Neutral

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.

Related Symbols 1

B BMRN BMRN

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #3,275

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

Comments

User Menu